6:18 PM
 | 
Jan 02, 2013
 |  BC Extra  |  Company News

IQWiG assesses Inlyta, aclidinium bromide

Germany's Institute for Quality and Efficiency in Health Care (IQWiG) said Inlyta axitinib from Pfizer Inc. (NYSE:PFE) provides a "significant additional benefit" over Nexavar sorafenib to treat advanced renal cell carcinoma (RCC) in patients who have failed treatment with a cytokine. The institute said in the Phase III AXIS 1032 trial there were no significant differences between the two drugs on overall...

Read the full 301 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >